NDA 050788 · Padagis US
Centany
Mupirocin · Topical
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 4, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
90
15 Phase 3, 5 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CENTANY · MUPIROCIN 2% · OINTMENT, TOPICAL · Discontinued · TE BX
Clinical trials
Interventional ClinicalTrials.gov studies with "Mupirocin" as an intervention, any sponsor and status, largest first.
- Mupirocin-Iodophor ICU Decolonization Swap Out TrialPivotal-lookingCompleted
Harvard Pilgrim Health CareAcademic, hospital or other
NCT03140423 · 353,323 participants · Start May 1, 2017 · Primary completion Nov 6, 2023
Drug: Arm 1. Routine Care (Mupirocin/CHG); Arm 2. Iodophor/CHG Decolonization · For: Staphylococcus Aureus
Sites: Riverside, California; San Jose, California; Thousand Oaks, California · 137 sites in all
- Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)Pivotal-lookingCompleted
Harvard Pilgrim Health CareAcademic, hospital or other
NCT00980980 · 74,256 participants · Start Sep 2009 · Primary completion Sep 2011
Drug: Chlorhexidine bath and nasal mupirocin · For: Methicillin-resistant Staphylococcus Aureus
Sites: Anchorage, Alaska; Thousand Oaks, California; Aurora, Colorado · 42 sites in all
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in SoldiersPivotal-lookingCompleted
Brooke Army Medical CenterFederal agency
NCT00289588 · 3,000 participants · Start Jan 2005
Drug: Mupirocin (drug) · For: Community-Acquired MRSA Infections; Abscesses; Cellulitis and 1 more
Sites: Fort Sam Houston, Texas
- Decolonization to Reduce After-Surgery Events of Surgical Site InfectionPivotal-lookingRecruiting
University of California, IrvineAcademic, hospital or other
NCT05586776 · 2,700 participants (planned) · Start Jan 17, 2023 · Primary completion Jun 2027
Drug: 4% Chlorhexidine Gluconate; 2% Mupirocin and 2 more · For: Surgical Site Infection
Sites: Newport Beach, California; Orange, California; Sacramento, California · 4 sites in all
- Project CLEAR - Changing Lives by Eradicating Antibiotic ResistancePivotal-lookingCompleted
University of California, IrvineAcademic, hospital or other
NCT01209234 · 2,140 participants · Start Jan 2011 · Primary completion Jan 2019
Drug: MRSA Decolonization · For: Methicillin-resistant Staphylococcus Aureus
Sites: Aliso Viejo, California; Anaheim, California; Downey, California · 24 sites in all
- A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.Pivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01876550 · 1,902 participants · Start Feb 2013 · Primary completion Feb 2014
Drug: Mupirocin Calcium Cream, 2%; Bactroban® Cream and 1 more · For: Secondarily Infected Traumatic Skin Lesions
- Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal MupirocinPivotal-lookingCompleted
Solventum US LLCIndustry
NCT01313182 · 1,874 participants · Start Mar 2011 · Primary completion Sep 2012
Drug: mupirocin calcium ointment, 2%; 3M Skin and Nasal Antiseptic · For: Surgical Site Infection
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interventions for impetigo.
Koning S, van der Sande R, Verhagen AP, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- End-stage renal disease.
Abbasi MA, Chertow GM, Hall YN · BMJ Clin Evid 2010 · Systematic Review
- Antimicrobial dressings for the prevention of surgical-site infection: systematic review and meta-analysis.
Yusuf SM, James J, Chong B, et al. · Br J Surg 2026 · Systematic Review, Meta-Analysis
- End stage renal disease.
Hall YN, Chertow GM · BMJ Clin Evid 2007 · Systematic Review
- Interventions for impetigo.
Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. · Cochrane Database Syst Rev 2004 · Systematic Review
- Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial.
Huang SS, Septimus E, Kleinman K, et al. · Lancet 2019 · Comparative Study, Randomized Controlled Trial
Sponsor: Padagis US
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.